Current Edition

CAR T

Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatment

Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …

Continue Reading →